DataSheet_1_Decreased TCF1 and BCL11B expression predicts poor prognosis for patients with chronic lymphocytic leukemia.docx by Taotao Liang (9944552)

“…<p>T cell immune dysfunction is a prominent characteristic of chronic lymphocytic leukemia (CLL) and the main cause of failure for immunotherapy and multi-drug resistance. …”

Elimination of the MRC rescues the prophase I delay due to constitutive Rad51 activation, while decreasing spore viability and increasing MI nondisjunction. by Andrew Ziesel (9422868)

The IC50 value of Tan in normal esophageal HET-1A cells. by Dong Yang (141041)

Difference in 3 month growth outcomes by treatment arm stratified by pathogen detection at 6 and 12 months of age. by Godfrey Guga (12152390)

Subjects:

Multiple trauma and hemorrhagic shock induce a transcriptional immune response. by Marc-Alexander Oestreich (13961375)

Raw data. by Changzhi Liu (518454)

Subjects:

Baseline characteristics of the subjects. by Changzhi Liu (518454)

Subjects:

Diet composition and nutritional values. by Taynara Aparecida Vieira (16401726)

“…The HSF group exhibited obesity (HSF 8.77 ± 2.64 <i><i>vs</i></i> C 3.09 ± 1.02, <i>p = </i>0.007), dyslipidemia (HSF 94.4 ± 19.1 <i><i>vs</i></i> C 26.7 ± 5.2, <i><i>p < </i></i>0.001), hypertension (HSF 141 ± 8 <i><i>vs</i></i> C 120 ± 4, <i>p = </i>0.001), insulin resistance (HSF 6.91 ± 1.38 <i><i>vs</i></i> C 2.47 ± 1.01, <i><i>p < </i></i>0.001), cardiac remodeling and dysfunction, cardiac inflammation, decreased metalloproteinase-2 (MMP-2) (HSF 0.43 ± 0.09 <i><i>vs</i></i> C 0.71 ± 0.07, <i>p = </i>0.009) and increased type III collagen (HSF 1.32 ± 0.27 <i><i>vs</i></i> C 1.00 ± 0.18, <i>p = </i>0.038). …”

Nutritional and metabolic analysis. by Taynara Aparecida Vieira (16401726)

“…The HSF group exhibited obesity (HSF 8.77 ± 2.64 <i><i>vs</i></i> C 3.09 ± 1.02, <i>p = </i>0.007), dyslipidemia (HSF 94.4 ± 19.1 <i><i>vs</i></i> C 26.7 ± 5.2, <i><i>p < </i></i>0.001), hypertension (HSF 141 ± 8 <i><i>vs</i></i> C 120 ± 4, <i>p = </i>0.001), insulin resistance (HSF 6.91 ± 1.38 <i><i>vs</i></i> C 2.47 ± 1.01, <i><i>p < </i></i>0.001), cardiac remodeling and dysfunction, cardiac inflammation, decreased metalloproteinase-2 (MMP-2) (HSF 0.43 ± 0.09 <i><i>vs</i></i> C 0.71 ± 0.07, <i>p = </i>0.009) and increased type III collagen (HSF 1.32 ± 0.27 <i><i>vs</i></i> C 1.00 ± 0.18, <i>p = </i>0.038). …”

Cardiovascular parameters. by Taynara Aparecida Vieira (16401726)

“…The HSF group exhibited obesity (HSF 8.77 ± 2.64 <i><i>vs</i></i> C 3.09 ± 1.02, <i>p = </i>0.007), dyslipidemia (HSF 94.4 ± 19.1 <i><i>vs</i></i> C 26.7 ± 5.2, <i><i>p < </i></i>0.001), hypertension (HSF 141 ± 8 <i><i>vs</i></i> C 120 ± 4, <i>p = </i>0.001), insulin resistance (HSF 6.91 ± 1.38 <i><i>vs</i></i> C 2.47 ± 1.01, <i><i>p < </i></i>0.001), cardiac remodeling and dysfunction, cardiac inflammation, decreased metalloproteinase-2 (MMP-2) (HSF 0.43 ± 0.09 <i><i>vs</i></i> C 0.71 ± 0.07, <i>p = </i>0.009) and increased type III collagen (HSF 1.32 ± 0.27 <i><i>vs</i></i> C 1.00 ± 0.18, <i>p = </i>0.038). …”

The decrease in sandstone permeability under different injection pressures as effective stress increases (0%NaCl saturated). by Bing Liang (3475652)

FTY720 decreased viability, proliferation, and motility and induced apoptosis in human hepatoblastoma cells. by Laura L. Stafman (6577184)

“…<p>(A) Following 24 hours of treatment with FTY720, the viability of HuH6 cells measured using the alamarBlue cell viability assay was significantly decreased (LD₅₀ = 8.4 μM, p ≤ 0.05). …”

The growth of co-transformed cells in the peritoneal cavity alters their cellular gene expression to mirror that of PEL biopsies. by Mitchell Hayes (5334887)

Validation of AgRP neuron-specific <i>Girk1</i> and <i>Girk2</i> deletion. by Youjin Oh (3308670)

Optical coherence tomography findings. by Eisuke Usui (12111855)

“…On OCT, layered plaques were more frequently present in the culprit vessels in the %hDPV-decrease group than in the %hDPV-increase group (85.0% vs. 50.6%, P = 0.01). …”

S1 Data - by Eisuke Usui (12111855)

“…On OCT, layered plaques were more frequently present in the culprit vessels in the %hDPV-decrease group than in the %hDPV-increase group (85.0% vs. 50.6%, P = 0.01). …”

Clinical demographics and angiographic findings. by Eisuke Usui (12111855)

“…On OCT, layered plaques were more frequently present in the culprit vessels in the %hDPV-decrease group than in the %hDPV-increase group (85.0% vs. 50.6%, P = 0.01). …”

Physiological parameters. by Eisuke Usui (12111855)

“…On OCT, layered plaques were more frequently present in the culprit vessels in the %hDPV-decrease group than in the %hDPV-increase group (85.0% vs. 50.6%, P = 0.01). …”

The injectable contraceptives depot medroxyprogesterone acetate and norethisterone enanthate substantially and differentially decrease testosterone and sex hormone binding globulin... by Chanel Avenant (409756)

“…<p dir="ltr">HIV acquisition risk with norethisterone (NET) enanthate (NET-EN) is reportedly less than for depo-medroxyprogesterone acetate intramuscular (DMPA-IM). We investigated the effects of these progestin-only injectable contraceptives on serum testosterone and sex hormone binding globulin (SHBG) levels, since these may play a role in sexual behavior and HIV acquisition. …”

Minimum quorum sensing inhibitory concentrations (MQSICs), minimum inhibitory concentrations (MICs), and concentrations inhibiting 50% of violacein production (IC50s) of compounds... by Jean Paul Dzoyem (6424445)

Subjects: